OccuLogix keeps an eye on new dry AMD (age-related macular degeneration) therapy
This article was originally published in Clinica
Executive Summary
TLC Vision and Vascular Sciences have formed a 50:50 joint venture, OccuLogix, that will focus on commercialising Vascular Sciences' new blood filtration method for treating dry age-related macular degeneration (AMD) - the leading cause of blindness in the over 50s in the Western world.